Resting Heart Rate in Chronic Obstructive Pulmonary Disease

Sponsor
Izmir Katip Celebi University (Other)
Overall Status
Completed
CT.gov ID
NCT04890080
Collaborator
(none)
110
1
51

Study Details

Study Description

Brief Summary

110 COPD patients who were participated in the PR program were included in the study. Resting Heart Rate , pulmonary functions, functional capacity, perception of dyspnea, quality of life and psychological symptoms compared before and after PR.

Condition or Disease Intervention/Treatment Phase
  • Other: Pulmonary Rehabilitation
N/A

Detailed Description

In many studies, it has been reported that baroreceptor activity and heart rate variability decrease and resting heart rate (RHR) increases in COPD patients due to changes in cardiac autonomic function. Among the recommendations regarding pulmonary rehabilitation (PR) and exercise training in COPD patients, approaches such as including practices targeting RHR and developing implementation strategies that improve the cardiovascular system are recommended. The primary aim of our study is to examine the effect of comprehensive exercise training consisting of breathing, aerobic and strengthening exercises on RHR in COPD patients, and secondarily to determine the factors that affect RHR change after PR in COPD patients.

110 COPD patients who were participated in the PR program were included in our retrospective study. Resting Heart Rate , pulmonary functions, functional capacity, perception of dyspnea, quality of life and psychological symptoms compared before and after PR.

Study Design

Study Type:
Interventional
Actual Enrollment :
110 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Improvement of Resting Heart Rate After Exercise Training and Its Predictors in Chronic Obstructive Pulmonary Diseases
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Apr 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: PR Group

Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program

Other: Pulmonary Rehabilitation
Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.

Outcome Measures

Primary Outcome Measures

  1. Resting Heart Rate [1 minute]

    number of beats per minute

Secondary Outcome Measures

  1. Functional Capacity [Change from baseline six minute walk distance at 8 week]

    Six Minute- walk test

  2. Dyspnea Assessment [Change from baseline dyspnea at 8 week]

    Medical Research Council Scale(MRC); the MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness. (min 1- max 5 point) Higher scores mean a worse outcome.

  3. Quality of Life Assessment [Change from baseline dyspnea at 8 week]

    St. George Respiratory Questionnaire; Scores range from 0 to 100, with higher scores indicating more limitations.

  4. Anxiety and Depression [Change from baseline dyspnea at 8 week]

    Hospital Anxiety and Depression (HAD); The HADS questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program
Exclusion Criteria:
  • With cardiovascular disease

  • With additional diseases such as diabetes

  • Receiving medical treatment that affects the autonomic nervous system

  • Patients receiving long-term oxygen therapy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Izmir Katip Celebi University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ilknur Naz, Assoc. Prof., Izmir Katip Celebi University
ClinicalTrials.gov Identifier:
NCT04890080
Other Study ID Numbers:
  • IKC111
First Posted:
May 18, 2021
Last Update Posted:
May 18, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ilknur Naz, Assoc. Prof., Izmir Katip Celebi University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2021